Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction

References

• Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476–479.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer 2010;116:4896–4901.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chevret S, Archimbaud E, . Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004;104:2467–2474.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan DW, . Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010;28:586–595.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369–377.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W . High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Kim HT, Cassileth PA, . Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010;116:5012–5021.
   PubMed Web of Science ®Google Scholar
• Lioure B, Pigneux A, Recher C, . No benefit of adding high-dose melphalan (HDM) suppported by autologous stem cell transplantation (SCT) over treatment with conventional induction, HD ARAC consolidation, and auto SCT (busulfan + HDM) for acute myelogenous leukemia (AML) under 60: first results of the randomized AML 2001 trial. Blood 2006;108(Suppl. 1): Abstract 608.
   Google Scholar
• Pautas C, Merabet F, Thomas X, . Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808–814.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 2011;50:187–193.
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, . Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10:337.
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Cortes JE, . Comparison of idarubicin + ara- C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:3575–3583.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Beran M, Cortes J, . Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006; 106:1099–1109.
   PubMed Web of Science ®Google Scholar
• Vey N, Kantarjian H, Beran M, . Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs 1999;17:89–95.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937–951.
   PubMed Web of Science ®Google Scholar
• Dastugue N, Payen C, Lafage-Pochitaloff M, . Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995;9:1491–1498.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, . Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Litzow MR, Othus M, Cripe LD, . Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 2010;148:217–225.
   PubMed Web of Science ®Google Scholar
• Yanada M, Borthakur G, Ravandi F, . Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 2008;93:1263–1265.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Rowe JM. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Curr Opin Hematol 2010;17:79–84.
   PubMed Web of Science ®Google Scholar